PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare, the worldwide leader in Diagnostic Imaging Technologies, announced today that it has entered into an agreement with DRAXIMAGE, a division of DRAXIS Health Inc. (NASDAQ:DRAX) (TSX:DAX) of Montreal, Canada, to become the exclusive distributor of DRAXIMAGE® Sestamibi upon its approval by the U.S. Food and Drug Administration (FDA) and the expiration of the primary innovator patent. An abbreviated New Drug Application (ANDA) for DRAXIMAGE® Sestamibi was submitted by DRAXIMAGE to the FDA in February 2007, and is currently under review.
